
Please try another search
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Name | Age | Since | Title |
---|---|---|---|
Joshua Michael Hare | 62 | 2014 | Co-Founder, Chief Science Officer & Chairman |
Elena Volpi | - | - | Member of Scientific Advisory Board |
Jeremy D. Walston | - | - | Member of Scientific Advisory Board |
Hidenori Arai | - | - | Member of Scientific Advisory Board |
Khoso Baluch | 67 | 2023 | Independent Director |
Roger J. Hajjar | 59 | 2024 | Independent Director |
Ursula Ungaro | 74 | 2021 | Independent Director |
Mohamed Wa'el Ahmed Hashad | 63 | 2023 | CEO & Director |
Richard N. Kender | 69 | 2024 | Independent Director |
Joe G. N. Garcia | - | - | Member of Scientific Advisory Board |
Rock Soffer | 42 | 2020 | Director |
Neha Motwani | 48 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review